A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

Completed · Phase 3 · Has a placebo group

Conditions studied: Urinary Bladder, Overactive

In brief

The purpose is to evaluate the efficacy of 5 and 10mg VESIcare® (solifenacin succinate) in patients with urgency who have overactive bladder syndrome.

Key facts

Study ID

NCT00454896

Run by

Astellas Pharma Inc

People needed

739

Starts

2004-05-01

Expected to finish

2005-09-01

Last updated by the study team

2014-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 1 urinary urgency episode/24h (on average) documented in a 3-day patient diary in the screening phase with or without urge incontinence, and usually with frequency and nocturia, described as OAB
• Patients may be included if they were never exposed to anticholinergic agents specified for the treatment of OAB. Patients may also be included if they have previously been treated with FDA-approved anticholinergic agents for the treatment of OAB such as oxybutynin chloride and are no longer receiving such treatment for a minimum of 14 days immediately preceding entry into the study. These previously treated patients must present at the investigative site on no anticholinergic agents and with the desire to receive treatment for OAB. Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study.
• Patients having urgency with or without urge incontinence accompanied by frequency of ≥8 episodes per 24 hours, and/or nocturia, for a period of ≥3 months prior to screening.

You may not qualify if…

• Previous treatment with darifenacin
• Duration of urgency with or without urge incontinence, usually accompanied with frequency and nocturia for <3 months
• Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the Investigator
• Evidence of a urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones
• Clinically significant outflow obstruction (benign prostatic hyperplasia) as determined by the Investigator

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Atherton, California, United States
• Study site — Carmichael, California, United States
• Study site — Escondido, California, United States
• Study site — Fresno, California, United States
• Study site — Los Angeles, California, United States
• Study site — Mission Hills, California, United States
• Study site — Mission Viejo, California, United States
• Study site — Salinas, California, United States
• Study site — Valley Village, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Denver, Colorado, United States
• Study site — New London, Connecticut, United States
• Study site — Norwalk, Connecticut, United States
• Study site — Trumbull, Connecticut, United States
• Study site — Waterbury, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Boyton Beach, Florida, United States
• Study site — Clearwater, Florida, United States
• Study site — Clearwater, Florida, United States
• Study site — Gainesville, Florida, United States
• Study site — Pembroke Pines, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — Tallahassee, Florida, United States
• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.